SCHEMBL2397208

SCHEMBL2397208

Cc1nc(Nc2cnccn2)sc1-c1cccc(S(=O)(=O)NCCO)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 15/20 0.49
PIK3CG P48736 13/20 0.49
PIK3CB P42338 10/20 0.49
PIK3CA P42336 9/20 0.49
PIK3C3 Q8NEB9 3/20 0.49
PI4KB Q9UBF8 3/20 0.49
PIK3C2B O00750 2/20 0.49
PI4KA P42356 2/20 0.49
PIK3C2A O00443 1/20 0.49
PRKDC P78527 1/20 0.49
CCNT1 O60563 2/20 0.44
CDK1 P06493 2/20 0.44
CCNB1 P14635 2/20 0.44
CCNA2 P20248 2/20 0.44
CDK2 P24941 2/20 0.44
CDK7 P50613 2/20 0.44
CDK9 P50750 2/20 0.44
CCNH P51946 2/20 0.44
BRD4 O60885 1/20 0.41
KDR P35968 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2397191 0.84 KDR (0.45) PIK3CDPIK3CGPIK3CBPIK3CAPIK3C3
SCHEMBL2399934 0.84 MEN1 (0.53) PIK3CDPIK3CGPIK3CBPIK3CACCNT1
SCHEMBL2400053 0.84 PIK3CD (0.68) PIK3CDPIK3CGPIK3CBPIK3CAPIK3C3
SCHEMBL2397182 0.83 PIK3CD (0.49) PIK3CDPIK3CGPIK3CBPIK3CAPIK3C3
SCHEMBL48631 0.81 PIK3CD (0.70) PIK3CDPIK3CGPIK3CBPIK3CAPIK3C3
SCHEMBL48602 0.78 PIK3CD (0.55) PIK3CDPIK3CGPIK3CBPIK3CAPIK3C3
SCHEMBL2395328 0.77 KDR (0.49) CDK2KDR
SCHEMBL2398099 0.75 MEN1 (0.45) PIK3CDPIK3CGPIK3CBPIK3CACCNT1
SCHEMBL2396335 0.75 PIK3CD (0.57) PIK3CDPIK3CGPIK3CBPIK3CACCNT1
SCHEMBL2397578 0.75 CDK2 (0.51) CCNT1CDK1CCNB1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017608-B2 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2011-09-13 US disclosed
EP-1608647-B1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-09 EP disclosed
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2006-07-06 US disclosed
EP-1608647-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS Novartis AG (CH) 2005-12-28 EP disclosed
WO-2004078754-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors MAP3K13, AKT3, MAP3K3 PIK3CD 42/4885PIK3CG 49/4885PIK3CB 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.